PathAI Resources

Artificial intelligence-powered digital pathology model supports that fibrosis is reduced by semaglutide in patients with NASH

Written by Admin | Nov 12, 2021 5:00:00 AM

Study Background

Significantly greater number of primary endpoint responders is detected in treated vs. placebo arms by AIM-NASH but not manual AIM-NASH detected dose-dependent treatment response in Ph2 study, in addition a statistically significant difference in proportion of subjects achieving endpoints. Harrison et al.
View Poster